In this issue:
Management of patients with pancreatic cancer using the “Right Track” model
A Novel HRD signature is predictive of FOLFIRINOX benefit in metastatic pancreatic cancer
Accuracy of models to prognosticate survival after surgery for pancreatic cancer
Multianalyte serum biomarker panel for early detection of PDAC
TP53 gain-of-function mutations are associated with differential prognosis in PDAC
Tumour mutational burden in real-world patients with pancreatic cancer
Outcomes after primary tumour resection of metastatic NETs
Major post-operative complications limit adjuvant therapy administration
Please login below to download this issue (PDF)